Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
The FDA must strengthen its capacity and create clearer pathways so that rare-disease patients can access lifesaving treatments sooner. Through my work with rare disease patients and families, I have seen firsthand the toll of delayed diagnoses, limited treatment options, and uncertainty. For these patients, the question is not only how quickly the FDA reviews a drug, but whether its system can evaluate therapies with patients’ realities in mind. For decades, single-arm trials — those without a randomized control group — were a standard route to approval for rare, rapidly progressing diseases. When no FDA-approved alternative exists, assigning patients to a placebo or an inferior treatment may be impractical or unethical. That approach was questioned last year after comments attributed to the FDA’s Center for Biologics Evaluation and Research raised doubts about whether single-arm data would still meet the bar for rare-disease approvals. FDA leadership has since backtracked, saying the comments do not reflect official policy. Developers still lack clarity as they design trials. Rare-disease treatments may need different routes to the same evidentiary standard. Trial delays, enrollment challenges, or prolonged reviews can mean months or years of uncertainty for people whose diseases are progressing. They may not live to see a lifesaving solution reach the market. I VOTED FOR TRUMP AND RFK JR. TO CLEAN UP OUR FOOD. THIS FDA NOMINEE THREATENS THAT PROMISE ... Patient stories cannot replace clinical evidence, but they can help regulators understand its consequences and context.
Original title: “The FDA’s new leadership must give rare disease patients a clearer path”
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
Original title: “This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking”
BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.
Original title: “BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs”
Over two years, patients experienced ... Travere Therapeutics. "In FSGS, the DUPLEX analysis adds to the evidence supporting the use of FILSPARI for patients without nephrotic syndrome, with higher complete proteinuria remission rates and lower observed rates of kidney failure compared to irbesartan. Together, these data reinforce the clinical value of FILSPARI across two rare, progressive kidney diseases.” · The final data readout from the Phase 2 SPARTAN Study, an open-label trial evaluating ... Over two years, patients experienced high rates of complete proteinuria remission and near physiologic eGFR decline, highlighting the potential for an oral, non-immunosuppressive therapy to address both key treatment goals early in the disease course," said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. "In FSGS, the DUPLEX analysis adds to the evidence supporting the use of FILSPARI for patients without nephrotic syndrome, with higher complete proteinuria remission rates and lower observed rates of kidney failure compared to irbesartan. Together, these data reinforce the cli SAN DIEGO--(BUSINESS WIRE)--Oct 2, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American … Incident Patients With IgA Nephropathy (IgAN) Demonstrated Stable eGFR With First-Line Sparsentan (SPAR) Over 2 Years in the SPARTAN Final Analysis Poster: TH-PO0453 Poster session: Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN Exhibit Hall A; October 22, 10:00 a.m.-12:00 p.m. MDT · Spatial transcriptomics reveals sparsentan-associated remodelling of complement-active renal niches in IgA Nephropathy Abstract: SA-OR048 Oral Abstract Session: Glomerular Diseases: Clinical Trial Results Mile High Ballroom 4A; October 24, 4:30 p.m.-6:00 p.m. Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) Without Nephrotic Syndrome (NS) in the Phase 3 DUPLEX Trial Poster: FR-PO0645 Poster session: Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research – ANCA/FSGS Exhibit Hall A; October 23, 10:00 a.m.-12:00 p.m.
Original title: “Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 | Dorchester Banner”
Capitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.
Original title: “Varda raises $251M to leverage gravity in space for drug production”
Kailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic ovarian syndrome.
Original title: “Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS”
Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.
Original title: “Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen”
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety…, Agenda Agenda of the PRAC meeting 28 September - 1 October 2026Draft Reference Number: EMA/PRAC/204838/2026…, PRAC statistics: October 2026 Monthly figures for PRAC outcomes based on the draft agenda. © European Medicines Agency,
Original title: “Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October”
Every missed patient in a rare disease clinical trial represents more than a recruitment challenge, it represents a missed opportunity to advance research for communities with limited treatment options. With more than 10,000 known rare diseases and only a small percentage with approved treatments, ... Every missed patient in a rare disease clinical trial represents more than a recruitment challenge, it represents a missed opportunity to advance research for communities with limited treatment options. With more than 10,000 known rare diseases and only a small percentage with approved treatments, the need for continued research is clear. Awareness remains one of the largest barriers in rare disease research. Patients, caregivers, and even healthcare providers may not recognize symptoms, connect those symptoms to a specific condition, or know that a clinical trial is available. Patient hesitancy is another significant barrier. For many rare disease patients, joining a trial may mean reconsidering a treatment routine that took years to establish. Complex protocols and restrictive eligibility criteria can make trial participation difficult for patients to fully understand. Patient-friendly education, online pre-screening, study videos, brochures, and clear site talking points can reduce uncertainty and help potential participants understand what to expect. These tools also allow sites to focus their time on the most qualified and informed referrals. Rare disease trials frequently compete for a limited patient population, making differentiation essential.
Original title: “Overcoming the Greatest Barriers in Rare Disease Patient Recruitment | Medpace”
rna targeting therapeutics for rare neuromuscular diseases progress challenges and the path toward personalized treatment
Original title: “RNA-targeting therapeutics for rare neuromuscular diseases: progress, challenges, and the path toward personalized treatment.”
primary surgical resection of localized cervical kaposiform hemangioendothelioma in a neonate a potentially curative strategy in selected patients
Original title: “Primary Surgical Resection of Localized Cervical Kaposiform Hemangioendothelioma in a Neonate: A Potentially Curative Strategy in Selected Patients.”